A National Program for Severe Asthma: The Canadian Severe Asthma Network (CSAN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00954850
Recruitment Status : Withdrawn (Subjects not entered into electronic database due to current construct of database and associated privacy legislations within Alberta.)
First Posted : August 7, 2009
Last Update Posted : August 24, 2012
Information provided by (Responsible Party):
Dilini Vethanayagam, University of Alberta

Brief Summary:

The Canadian Severe Asthma Network (CSAN) was developed to gain a better understanding of the clinical, environmental, socio-economic, work-related, and biological characteristics of severe asthmatics (SA) that may account for poor response to clinically available therapies for asthma.

This network of clinical and basic researchers will be a means by which Canadian investigators can develop and conduct research in this small patient group, which could lead to better clinical management of SA.

Patient information will be entered into the CSAN database (created by PI Dr. Vethanayagam in connection with Mr. Jack Yeung) and will help researchers and doctors from multiple hospitals and universities across Canada to understand this subpopulation of asthmatics better. It will help to answer questions regarding SA epidemiology, asthma education, inflammatory monitoring, risks of near fatal asthma (NFA), symptom perception, changes in lung structure and function, co-morbidities, and the effectiveness of developing regional severe asthma clinics. Two of the early projects the investigators will be working on are psychosocial co-morbidities in asthma and medication coverage related to asthma.

There will also be biobanking of sputum samples and/or bronchoscopy samples (such as BALs & lung washings) that are being obtained for clinical purposes. Also, for those consented for biobanking blood and urine will be collected, separate from clinical care, and stored in the biobank. The Canadian Biosample Repository (CBSR) will be storing our biobanked samples. The investigators will be following the CBSR policies for storage and security. Tissue research will be conducted in the future, and separate ethics approval will be obtained for each project.

Condition or disease
Severe Persistent Asthma

  Show Detailed Description

Study Type : Observational
Actual Enrollment : 0 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: A National Program for Severe Asthma: The Canadian Severe Asthma Network
Study Start Date : June 2010
Actual Primary Completion Date : August 2012
Actual Study Completion Date : August 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Severe asthmatics
Main study group
Mild-moderate asthmatics
Control group

Biospecimen Retention:   Samples Without DNA
If consented to by the patient, extra clinical specimens - sputum plugs, sputum supernatant, blood and urine will be stored. If patients undergo a clinical bronchoscopy, mucosal biopsies x 2 and bronchoalveolar lavage will be stored.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Severe asthmatics as the primary study group, mild-moderate asthmatics as the control group

Inclusion Criteria:

  • Adults (18 and older) with physiologically confirmed SA or mild-moderate asthma and followed by an asthma specialist for at least 6 months.
  • Must agree to have regular clinic visits (minimum 3-4 per year for SA, 1-2 for mild-moderate asthma).
  • Must have good compliance with medications Patients with asthma and COPD.

Exclusion Criteria:

  • Malignancy and other significant medical conditions that will impact follow up within this program.
  • Those less than 18 years of age.
  • Concomitant interstitial lung disease, sarcoidosis, other significant lung disease.
  • Those who have had a transplant.
  • Significant travel with work.
  • Unable to make appointments (every three to six months over 2 years).
  • Those residing in another country or planned absence for more than one month.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00954850

Canada, Alberta
University of Alberta Hospital
Edmonton, Alberta, Canada, T6G 2B7
Sponsors and Collaborators
University of Alberta
Principal Investigator: Dilini Vethanayagam, MD University of Alberta

Additional Information:
Responsible Party: Dilini Vethanayagam, Associate Professor, Medicine (Pulmonary), University of Alberta Identifier: NCT00954850     History of Changes
Other Study ID Numbers: CSAN Protocol
First Posted: August 7, 2009    Key Record Dates
Last Update Posted: August 24, 2012
Last Verified: August 2012

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases